Vest Financial LLC reduced its stake in shares of McKesson Corporation (NYSE:MCK - Free Report) by 10.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 13,859 shares of the company's stock after selling 1,570 shares during the period. Vest Financial LLC's holdings in McKesson were worth $10,156,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of MCK. Oppenheimer Asset Management Inc. lifted its stake in shares of McKesson by 54.0% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 4,541 shares of the company's stock valued at $3,056,000 after buying an additional 1,592 shares in the last quarter. Dynamic Advisor Solutions LLC boosted its holdings in McKesson by 16.6% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 778 shares of the company's stock worth $524,000 after buying an additional 111 shares during the period. Cambridge Investment Research Advisors Inc. boosted its holdings in McKesson by 18.9% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 23,033 shares of the company's stock worth $15,501,000 after buying an additional 3,659 shares during the period. Acadian Asset Management LLC boosted its holdings in McKesson by 22.0% in the 1st quarter. Acadian Asset Management LLC now owns 378,926 shares of the company's stock worth $254,979,000 after buying an additional 68,294 shares during the period. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in McKesson by 4.3% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 183,258 shares of the company's stock worth $123,332,000 after buying an additional 7,556 shares during the period. 85.07% of the stock is owned by institutional investors.
Analyst Ratings Changes
MCK has been the subject of several analyst reports. Wall Street Zen raised shares of McKesson from a "hold" rating to a "buy" rating in a report on Sunday, September 28th. Evercore ISI raised their price objective on shares of McKesson from $800.00 to $825.00 and gave the stock an "outperform" rating in a report on Wednesday, September 24th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of McKesson from $775.00 to $856.00 and gave the stock a "buy" rating in a report on Wednesday, September 24th. Citigroup raised their price target on shares of McKesson from $820.00 to $860.00 and gave the company a "buy" rating in a report on Wednesday, September 24th. Finally, Morgan Stanley raised their price target on shares of McKesson from $810.00 to $857.00 and gave the company an "overweight" rating in a report on Wednesday, September 24th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $834.54.
Get Our Latest Analysis on McKesson
McKesson Price Performance
Shares of NYSE:MCK opened at $768.79 on Tuesday. The firm has a fifty day moving average price of $708.64 and a two-hundred day moving average price of $707.37. McKesson Corporation has a one year low of $492.39 and a one year high of $776.14. The company has a market cap of $95.62 billion, a price-to-earnings ratio of 30.65, a PEG ratio of 1.38 and a beta of 0.52.
McKesson (NYSE:MCK - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $8.26 earnings per share for the quarter, missing the consensus estimate of $8.33 by ($0.07). The company had revenue of $97.83 billion for the quarter, compared to analysts' expectations of $95.93 billion. McKesson had a net margin of 0.84% and a negative return on equity of 196.66%. The business's quarterly revenue was up 23.4% compared to the same quarter last year. During the same quarter last year, the business posted $7.88 EPS. Equities research analysts expect that McKesson Corporation will post 32.77 EPS for the current fiscal year.
McKesson Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 1st. Investors of record on Tuesday, September 2nd were given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date was Tuesday, September 2nd. This is a boost from McKesson's previous quarterly dividend of $0.71. McKesson's dividend payout ratio is 13.08%.
Insiders Place Their Bets
In other McKesson news, CEO Brian S. Tyler sold 11,930 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $705.63, for a total value of $8,418,165.90. Following the transaction, the chief executive officer owned 4,012 shares in the company, valued at approximately $2,830,987.56. The trade was a 74.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the business's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $663.67, for a total transaction of $218,347.43. Following the completion of the transaction, the chief accounting officer owned 657 shares in the company, valued at $436,031.19. The trade was a 33.37% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,189 shares of company stock worth $16,722,190. 0.08% of the stock is owned by corporate insiders.
McKesson Company Profile
(
Free Report)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider McKesson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and McKesson wasn't on the list.
While McKesson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.